Introduction {#sec1}
============

Dental implants are devices that are surgically placed in the mandibular or maxillary bone to support or retain prosthodontic or orthodontic appliances.[@bib1], [@bib2] For a long-term clinical success of dental implants, a direct and intimate contact between the bone and the implant surface must exist. The formation of such an implant--bone interface is termed osseointegration.[@bib3], [@bib4], [@bib5] If the implant does not osseointegrate, it leads to failure, resorption of the alveolar bone and loss of the implant.[@bib6] Currently, the most widely used dental implant material is titanium.[@bib7] A number of factors may lead to failure of osseointegration, such as poor bone quality and volume, periodontitis, poor systematic health, tobacco use, and poor oral hygiene.[@bib8], [@bib9] Additionally, implant characteristics, such as surface texture, shape and material, also play key roles towards osseointegration.[@bib7], [@bib10]

Therefore, a dental implant material must fulfil a number of requirements in order to be used in clinical settings.[@bib7], [@bib11] First, the surface of the dental implant must be hydrophilic to promote cellular adhesion. Hydrophilicity may be increased by means of numerous surface treatments and coatings. Second, the shape of the implant must suit the site of application. In addition, coatings of osseoconductive materials, such as calcium phosphates and hydroxyapatite (HA), on the implant surface have been observed to promote the surface properties of dental implants.[@bib12], [@bib13] However, even with the aforementioned surface treatments, implants are known to fail.[@bib9] For example, the poor mechanical properties and delamination of the bioactive layer from the titanium surface contributes to the failure of osseointegration. The coating process involves implant treatment at high temperatures that leads to the formation of weaker calcium phosphate phases that might break off from the deeper layers of the coating.[@bib7] More recently, immobilizing bioactive and osseoconductive drugs and growth factors have been advocated to improve osseointegration.[@bib14]

Systematic bone diseases, such as osteoporosis, affect bone physiology and osseointegration.[@bib15], [@bib16] The prevalence of osteoporosis is on the rise, posing a key healthcare problem.[@bib17], [@bib18] Bisphosphonates (BPs) are a class of drugs that are commonly used to treat osteoporosis.[@bib17], [@bib18], [@bib19] Although BPs\' prolonged systemic use may cause bisphosphonate-related osteonecrosis of the jaws (BRONJ), their topical application has resulted in a positive effect on periodontal health and bone formation.[@bib20], [@bib21], [@bib22] BPs reduce bone resorption by inhibiting osteoclasts by inhibiting the farnesyl diphosphate synthase (FPPS) enzyme in the HMG-CoA reductase pathway.[@bib23] BPs have a higher affinity to bone cells compared to other tissues and are selective in their actions.[@bib24] Due to BPs\' anti-resorptive action, they have been immobilized on the surface of titanium dental implants. It has been further suggested that such coatings have a positive effect on new bone formation around the dental implants.[@bib25] However, other studies have suggested that there is no difference between BP-releasing implants, HA-coated and uncoated implants.[@bib26] Hence, there seems to be a controversy regarding the use of BP-releasing dental implants. Therefore, the aim of this systematic review is to analyse the currently available data concerning the clinical and experimental efficacy of BP-releasing titanium implants such that their potential in clinical oral implant dentistry may be ascertained.

Materials and Methods {#sec2}
=====================

Focused question {#sec2.1}
----------------

A focused question was constructed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Participants Intervention Control Outcomes (PICO) protocol.[@bib27] The focused question was, 'What is the effect of a bisphosphonate-releasing coating on the osseointegration of titanium dental implants?'

Literature search and eligibility criteria {#sec2.2}
------------------------------------------

A number of databases (PubMED/MEDLINE, ISI Web of Knowledge, Embase and Google Scholar) were searched electronically using the combination of keywords 'dental implant'; 'bisphosphonate' and 'titanium' from 1978 up to and including May 2016 for articles addressing the focused question. The inclusion criteria were the following: (1) Human studies, (2) Animal studies, (3) Original studies, (4) Articles published in English, and (5) BP-coated titanium implants. The following types of studies were excluded: (1) Cell studies, (2) Reviews, (3) Non-titanium implants, and (4) Letters to the editor.

Two reviewers, S.N. and Z.K., conducted the literature search using the above keywords and eligibility criteria. Additionally, the reference lists of the acquired full-texts were scanned manually for any additional articles relevant to the review. Any disagreements were settled by discussion among the reviewers. All included studies were analysed for the focused question, and relevant information was extracted. A flow diagram for the search methodology employed for conducting this review is illustrated in [Figure 1](#fig1){ref-type="fig"}.Figure 1Search methodology employed for this study.Figure 1

Quality assessment {#sec2.3}
------------------

The quality of the included studies was assessed using a modified scale previously described by Antczak et al.[@bib28] and Jadad et al.[@bib29] The following characteristics of the studies were assessed: calculation of sample size, description of appropriate measurement methods, appropriate statistics, error analysis and blinding. The quality of each study was hence designated as low, medium and high.

Results {#sec3}
=======

Search results {#sec3.1}
--------------

Of the 255 articles that resulted in the primary search, 11 articles fulfilled the criteria to be included in this review. Eight studies were experimental,[@bib25], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35] two studies were clinical,[@bib36], [@bib37] and one study was both-clinical and animal.[@bib26] The general characteristics and main outcomes of included studies are displayed in [Table 1](#tbl1){ref-type="table"}.Table 1General characteristics and main outcomes of the selected studies.Table 1Authors; yearStudy designSubjects (n)No. of implants placed (n)Duration of studyImplant surfaceBP usedMain outcomesControlTestDenissen et al.; 2000[@bib26]Experimental/clinical15 goats; 10 patientsAnimals: 80; clinical: 23Animal: 3 months; clinical: 1 yearHABP + HAAlendronateComparable outcomes in both groups.Langhoff et al.; 2008[@bib38]Experimental1 sheep78 weeksUncoated (sand-blasted; etched)BP; CaP; anodized heat treatment; Collagen I + Chondroitin SulphateAlendronateComparable outcomes in all groups.Abtahi et al.; 2010[@bib37]Clinical5 patients356 monthsUncoatedBP + FibrinogenPamidronate and ibandronateResonance frequency values and radiographic bone formation suggests BP improves osseoinegration.Lee et al.; 2011[@bib35]Experimental18 rats364 weeksUncoatedBP + anodized heat treatment; heat treatmentIbandronateBP increased removal torque and enhanced osteoblast activity.Abtahi et al.; 2012[@bib36]Clinical16 patients326 monthsUncoatedBP + FibrinogenPamidronate and ibandronateBP increased resonance frequency values and decreased marginal bone lossAbtahi et al.; 2013[@bib25]Experimental40 rats402 weeksUncoatedLocal BP + Fibrinogen; systemic BPZoledronateBP increased removal torque.Alghamdi et al.; 2014[@bib30]Experimental30 osteoporotic rats; 30 healthy rats604 weeksUncoatedBP; BP-CaP; CaPAlendronateBP-CaP increased new bone formation.Nepal et al.; 2014[@bib34]Experimental8 rats84 weeksUncoated (Ti--Zr alloy)BP + anodized heat treatmentIbandronateBP increased new bone formation and resonance frequency values.Pyo et al.; 2014[@bib31]Experimental20 rats408 weeksCaPBP + CaP (8--800 μg/mL)ZoledronateBP increased volume of new bone formed but had no effect on bone-implant contact.Karlsson et al.; 2015[@bib33]Experimental20 rats408 weeksMesoporous TiO~2~Mesoporous BP-TiO~2~AlendronateBP increased new bone formation and remained bound to bone within 500 μm of implant site.Pura et al.; 2016[@bib32]Experimental15 dogs3012 weeksPorous; HA-porousBP - porous (0.02--0.18 mg/cm^2^)AlendronateBP (0.06 mg/cm^2^) increased new bone formation but had no effect on bone ingrowth.[^1]

Main outcomes and quality of studies {#sec3.2}
------------------------------------

In nine studies (82%),[@bib25], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37] BP coated implants resulted in higher osseointegration, as indicated by higher resonance frequency values, removal torque, bone-to-implant contact and new bone formation. In two studies (18%),[@bib26], [@bib38] there was no difference between the osseointegration of BP-coated implants and controls. Additionally, in one study, it was observed that BP remained within 500 μm of implant site.[@bib33] As shown in [Table 2](#tbl2){ref-type="table"}, the quality of seven studies was rated as low[@bib25], [@bib32], [@bib33], [@bib34], [@bib35], [@bib37], [@bib38] while four studies were rated as medium.[@bib26], [@bib30], [@bib31], [@bib36]Table 2Results of the quality assessment of the selected studies.Table 2Authors; yearSample size calculation providedAppropriate measurement methodsAppropriate statisticsError analysis providedBlindingQualityDenissen et al.; 2000[@bib26]NoYesYesYesNoMediumLanghoff et al.; 2008[@bib38]NoYesYesNoNoLowAbtahi et al.; 2010[@bib37]NoYesYesNoNoLowLee et al.; 2011[@bib35]NoYesYesNoNoLowAbtahi et al.; 2012[@bib36]NoYesYesNoYesMediumAbtahi et al.; 2013[@bib25]NoYesYesNoNoLowAlghamdi et al.; 2014[@bib30]NoYesYesNoYesMediumNepal et al.; 2014[@bib34]NoYesYesNoNoLowPyo et al.; 2014[@bib31]NoYesYesNoYesMediumKarlsson et al.; 2015[@bib33]NoYesYesNoNoLowPura et al.; 2016[@bib32]NoYesYesNoNoLow

Discussion {#sec4}
==========

Studies suggested that BP-releasing dental implants may have a positive effect on osseointegration. BPs reduce bone resorption by inhibiting and promoting apoptosis of osteoclasts.[@bib39], [@bib40] Periodontal effects of BPs have been observed previously. The topical application of BP gel has been suggested to augment the efficacy of scaling and root planning resulting in improved periodontal parameters.[@bib20], [@bib21] Similarly, BP-releasing dental implants have been observed to reduce the marginal bone loss compared to those without a BP-releasing coating.[@bib36] Previously, such growth factors as bone morphogenetic protein 2 (BMP-2) have been immobilized on dental implants to improve osseointegration.[@bib41] To date, BPs have been coated on dental implants in numerous ways. Due to BPs\' high affinity to hydroxyapatite (HA) and calcium phosphates, they may be complicated with sprayed plasma or biomimetic coatings on dental implants.[@bib26], [@bib31] Alternatively, BPs have been attached to the titanium surface via fibrinogen,[@bib25] by anodization and heat treatment[@bib35] or by immobilization on a porous surface.[@bib33] For effective drug delivery, a slow sustained release of the pharmacological agent from the delivery device or medium is required.[@bib42] Hence, dental implants delivering osseoconductive agents at a slow and sustained manner into the surrounding bone may improve osseointegration. There are differences among the various types of different BPs in affinities for binding to HA.[@bib43] To the best of our knowledge, to date, there have been no studies conducted to investigate the difference in release and effect of different BPs from coated implants. Hence, studies are indeed needed to find the optimal BP for immobilization on dental implants. Moreover, bisphosphonates are known as to be anti-resorptive drugs that inhibit osteoclasts mostly by bone metabolism. In a clinical trial on 16 patients, bisphosphonate-eluting fibrinogen coating on implants revealed markedly improved mechanical fixation.[@bib24]

As demonstrated by Nepal et al.[@bib34] Karlsson et al.[@bib33] and Lee et al.,[@bib35] anodization of titanium surfaces creates a layer of porous TiO~2~, which makes it easier to load BPs for effective *in-situ* delivery to periodontal bone. However, the long-term efficacy of such coatings, owing to the lack of clinical studies, is not clear. Although animal studies suggest that such coated implants may have an osseoconductive effect, animal studies do not necessarily translate to positive clinical effects. Therefore, more studies are required to investigate anodized BP coatings on dental implants. Attachment of BP to titanium surfaces via an intermediate layer of fibrinogen may also be an effective way to improve osseointegration. A series of animal and human studies by Abtahi et al.[@bib25], [@bib36], [@bib37] suggests that BP-coated dental implants may reduce marginal bone loss. However, in the human trials, the patient follow-up period was only 6 months,[@bib36], [@bib37] and hence, the long-term clinical efficacy of such coatings is not unknown.

Although the systematic effect of BPs on osseointegration is not clear,[@bib19], [@bib44] the major concern of BRONJ due to BP still exists. Local delivery of BPs to via immobilization on dental implants may overcome the risk of BRONJ. Abtahi et al.[@bib25] have observed that local delivery of BPs has a positive impact on the osseointegration in rats receiving systemic BPs. Additionally, in a study by Karlsson et al.,[@bib33] BP delivered via dental implants remained within 500 μm of the implant site. These results suggest that BPs may be safe and may have minimal risk of inducing necrosis of the bone. However, these results should be confirmed by more in-depth studies before BP-coated dental implants may be used in clinics.

Osseointegration of BP-releasing implants have been monitored in patients in only two studies.[@bib36], [@bib37] The follow-up of both of these two studies was only 6 months. To date, no follow-up articles have been published documenting the long-term outcomes of those studies. Furthermore, it is unclear whether the effect of BP release is dose-dependent. Pyo et al.[@bib31] have reported that increasing the dose of BP from 8 to 80 μg/mL increases new bone formation in rats but has little effect on bone-implant contact. However, Pura et al.[@bib32] have observed that 0.06 mg/cm^2^ of BP on implant surface is optimal for enhancing bone formation, but no effect is observed on bone-in growth *in vivo*. Similarly, clinical studies by Abtahi et al.[@bib36], [@bib37] have used BPs in a concentration of less than 1 μg/cm.[@bib2] But none of the studies reported to date had investigated the effect of altering the dose of BP in human subjects.

Conclusions {#sec5}
===========

Bisphosphonate-loaded surface coatings may have a positive effect on osseointegration of dental implants. However, more well-designed clinical studies are required to confirm the coatings\' osseoconductive effect. Alendronate is the most frequently used BP in the studies in combination with HA, collagen 1, chondroitin sulphate, and calcium phosphate, heat treatment and titanium oxide that revealed significant new bone formation. The pamidronate and ibandronate used together and separately were assessed in combination with fibrinogen and heat treatment and resulted in improved osseointegration and decreased marginal bone loss. However, the use of zoledronate with fibrinogen and calcium phosphate in two studies showed increased bone formation and increased removal torque with no bone implant effect. To date, the above-mentioned four types of BP coated implants were treated and analysed through animal and human studies to determine the effect. These studies sought to improve the osseointegration and fixation of dental implants. However, more research and clinical trials with various other implant coatings are needed to establish better evidence for successful outcomes.

Limitations {#sec5.1}
-----------

Although the outcomes of the reviewed studies are promising, this study has several limitations. For instance, the quality assessment of the literature revealed that there might be numerous sources of bias. These findings are based on data extracted primarily from animal studies and only two clinical studies.[@bib36], [@bib37] None of the studies supported its sample size by a suitable statistical calculation. Furthermore, the error analysis was included in only one study,[@bib26] and only three studies were blinded.[@bib30], [@bib31], [@bib36] These sources of bias may have contributed to a number of the positive outcomes documented in the studies. There is not sufficient evidence to validate the efficacy of BP-coated dental implants. Further research and unbiased clinical trials are warranted.
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